Batoclimab as an add‐on therapy in neuromyelitis optica spectrum disorder patients with acute attacks

Wang, Yuge; Zhong, Xiaonan; Wang, Honghao; Peng, Yu; Shi, Fu‐Dong; Jia, Dongmei; Yang, Huan; Zeng, Qingbei; Quan, Chao; ZhangBao, Jingzi; Lee, Michael; Qi, Jun; Chen, Xiaoxiang; Qiu, Wei

doi:10.1111/ene.15561

Euro J of Neurology

2022

DOI: 10.1111/ene.15561

|View full text |Cite

Batoclimab as an add‐on therapy in neuromyelitis optica spectrum disorder patients with acute attacks

Yuge Wang

Xiaonan Zhong

Honghao Wang

et al.

Abstract: Neuromyelitis optica spectrum disorder (NMOSD) is a rare neurological inflammatory disorder, characterized by recurrent myelitis and optic neuritis, which can lead to severe paralysis and blindness.It is reported that more than 75% of NMOSD patients are seropositive for aquaporin-4 immunoglobulin G (AQP4-IgG) [1].

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

References 20 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Kuempfel¹,

Giglhuber²,

Aktaş³

et al. 2023

J Neurol

View full text Add to dashboard Cite

This manuscript presents practical recommendations for managing acute attacks and implementing preventive immunotherapies for neuromyelitis optica spectrum disorders (NMOSD), a rare autoimmune disease that causes severe inflammation in the central nervous system (CNS), primarily affecting the optic nerves, spinal cord, and brainstem. The pillars of NMOSD therapy are attack treatment and attack prevention to minimize the accrual of neurological disability. Aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) are a diagnostic marker of the disease and play a significant role in its pathogenicity. Recent advances in understanding NMOSD have led to the development of new therapies and the completion of randomized controlled trials. Four preventive immunotherapies have now been approved for AQP4-IgG-positive NMOSD in many regions of the world: eculizumab, ravulizumab - most recently-, inebilizumab, and satralizumab. These new drugs may potentially substitute rituximab and classical immunosuppressive therapies, which were as yet the mainstay of treatment for both, AQP4-IgG-positive and -negative NMOSD. Here, the Neuromyelitis Optica Study Group (NEMOS) provides an overview of the current state of knowledge on NMOSD treatments and offers statements and practical recommendations on the therapy management and use of all available immunotherapies for this disease. Unmet needs and AQP4-IgG-negative NMOSD are also discussed. The recommendations were developed using a Delphi-based consensus method among the core author group and at expert discussions at NEMOS meetings.

show abstract

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Kuempfel¹,

Giglhuber²,

Aktaş³

et al. 2023

J Neurol

View full text Add to dashboard Cite

show abstract

Efgartigimod as Rescue Treatment in Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Case Report

Li,

Xu,

Huang

et al. 2024

Heliyon

View full text Add to dashboard Cite

The changing landscape of thyroid eye disease: current clinical advances and future outlook

Moledina,

Damato,

Lee

2024

Eye

View full text Add to dashboard Cite

Aims This review aims to provide an overview of the current understanding of TED and its pathophysiology. To describe the evidence base for current consensus treatment recommendations and newer biological therapies available as well as to present future therapeutic research. Methods We reviewed and assessed the peer-reviewed literature placing particular emphasis on recent studies evaluating the pathophysiology of TED, landmark trials forming the basis of current management and recent clinical trials informing future therapeutics. Searched were made in MEDLINE Ovid, Embase Ovid, US National Institutes of Health Ongoing Trials Register and EU Clinical Trials Register. Keywords included: “Thyroid Eye Disease”, “Graves Orbitopathy”, “Thyroid Orbitopathy” and “Graves’ Ophthalmopathy”. Results and conclusions The pathophysiology of TED involves a complex array of cellular and humoral based autoimmune dysfunction. Previous therapies have been broad-based acting as a blunt instrument on this mechanism with varying efficacy but often accompanied with a significant side effect profile. The recent development of targeted therapy, spearheaded by Teprotumumab has led to an array of treatments focusing on specific components of the molecular pathway optimising their impact whilst possibly minimising their side effect profile. Future challenges involve identifying the most effective target for each patient rather than any single agent being a panacea. Long-term safety profiles will require clarification as unintended immunological consequence downstream may become manifest as seen in other diseases. Finally, future novel therapeutics will entail significant expenditure and may lead to a divergence of available treatment modalities between healthcare systems due to funding disparities.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

334 Leonard St

Brooklyn, NY 11211

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Batoclimab as an add‐on therapy in neuromyelitis optica spectrum disorder patients with acute attacks

Cited by 5 publications

References 20 publications

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Efgartigimod as Rescue Treatment in Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Case Report

The changing landscape of thyroid eye disease: current clinical advances and future outlook

Contact Info

Product

Resources

About